Published:
Wednesday,
April 14, 2021
20:39
–
–
–
The director of the Danish Medicines Agency, Tanja Erichsen, has fainted when appearing with other authorities health agencies to announce the definitive elimination of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford from their immunization plan following the occurrence of thrombolic events.
Erichsen has collapsed in full press conference, and the assistants have proceeded to his immediate attention. Fortunately, he has recovered within minutes.
Denmark suspended the administration of the AstraZeneca drug on March 11, after several cases of young people who had suffered thrombosis after receiving it. In the European country, a 60-year-old woman has died from one of these episodes after being inoculated. About 150,000 people have received the COVID-19 vaccine from AstraZeneca in Denmark, which had committed 5.2 million doses and has around 220,000 doses in stock.
Now, the authorities must offer another vaccine to those already immunized with the first dose, which they will re-enter the vaccination queue.
The suspension of the use of the immunizer will delay the end of the Danish vaccination campaign until August 31, according to the vaccination schedule updated after the decision is known. In addition, Johnson & Johnson’s drug application has been temporarily frozen, also possibly linked to thrombi. Denmark received the first doses of it on Wednesday, a total of 38,400.
Following the announcement, the Czech Republic has offered to buy the remaining AstraZeneca doses in Denmark. “We are ready to buy (the vaccine from) AstraZeneca from Denmark“, has transferred the Minister of the Interior, Jan Hamacek, through his Twitter account.
For the moment, it is not clear if the leftover doses are for sale and neither if the transaction between the two countries would be allowed under the rules of the European Union.
–